Advertisement

Gynecologic care for breast cancer survivors: assisting in the transition to wellness

Published:October 24, 2011DOI:https://doi.org/10.1016/j.ajog.2011.10.858
      Currently, there are >2 million survivors of breast cancer in the United States. Two years after cancer treatment, patients may transition to primary care providers and/or gynecologists. Many of these survivors may have difficulties with menopausal symptoms. If they do not know already, some of these women may want or need risk assessment for hereditary- or treatment-induced second cancers. At least 20% will also have significant psychologic, sexual, and/or relationship difficulties that require attention. All of the women will need assistance to learn and follow recommendations for surveillance, detecting recurrence, and promoting wellness. Thus, gynecologists play a critical role in helping these patients in their health care transitions. To assist the gynecologists, we have reviewed the evaluation and management of common sequelae of breast cancer diagnoses and treatments.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jemal A.
        • Siegel R.
        • Xu J.
        • Ward E.
        Cancer statistics, 2010.
        CA Can J Clin. 2010; 60: 277-300
      1. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses' health study. N Engl J Med 199;325:756-62.

        • American Cancer Society
        Cancer facts and figures, 2010.
        American Cancer Society, Inc, Atlanta, GA2010
        • National Cancer Institute
        Stat bite: Number of cancer survivors by site, 2003.
        (Accessed Sept. 9, 2011)
        • Erickson C.
        • Salsberg E.
        • Forte G.
        • Buuinooge B.A.
        • Goldstein M.
        Future supply and demand for oncologists: challenges to assuring access to oncology services.
        J Oncol Pract. 2007; 3: 79-86
        • Patlak M.
        • Levit L.
        Ensuring quality cancer care through the oncology workforce: Institute of Medicine, National Cancer Policy Forum.
        National Academies Press, Washington, DC2009
        • Mao J.J.
        • Bowan M.A.
        • Stricker C.T.
        • et al.
        Delivery of survivorship care by primary care physicians: the perspective of breast cancer patients.
        J Clin Oncol. 2009; 27: 933-938
        • Earle C.C.
        • Burstein H.J.
        • Winer E.P.
        • Weeks J.C.
        Quality of non-breast cancer health maintenance among elderly breast cancer survivors.
        J Clin Oncol. 2003; 21: 1447-1451
        • Hewitt M.
        • Greenfield S.
        • Stovall E.
        • et al.
        From cancer patient to cancer survivor: lost in transition.
        National Academies Press, Washington, DC2006
        • Buzaglo J.
        Summary report: cancer survivor registry: the Breast Cancer MAP (mind affects the physical) project.
        Cancer Support Community, Philadelphia, PA2010
        • Foulkes W.D.
        Inherited susceptibility to common cancers.
        N Engl J Med. 2008; 13 (359): 2143-2153
        • American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins: Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists
        ACOG practice bulletin no. 103: Hereditary breast and ovarian cancer syndrome.
        Obstet Gynecol. 2009; 113: 957-966
        • Daly M.B.
        • Axilbund J.E.
        • Buys S.
        • et al.
        • National Comprehensive Cancer Network
        Genetic/familial high-risk assessment: breast and ovarian.
        J Natl Compr Canc Netw. 2010; 8: 562-594
        • Burke W.
        • Daly M.
        • Garber J.
        • et al.
        Recommendations for follow-up care of individuals with an inherited predisposition to cancer BRCA1 and BRCA2: Cancer Genetics Studies Consortium.
        JAMA. 1997; 277: 997-1003
        • Kauff N.D.
        • Domchek S.M.
        • Friebel T.M.
        • et al.
        Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 and BRCA2 associated breast and gynecologic cancer: a multicenter, prospective study.
        J Clin Oncol. 2008; 26: 1331-1337
        • Rebbeck T.R.
        • Lynch H.T.
        • Neuhausen S.L.
        • et al.
        Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations: prevention and observation of surgical endpoints study group.
        N Engl J Med. 2002; 346: 1616-1622
        • Kauff N.D.
        • Satagopan J.M.
        • Robson M.E.
        • et al.
        Risk reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation.
        N Engl J Med. 2002; 346: 1609-1615
        • Domchek S.M.
        • Friebel T.M.
        • Singer C.F.
        • et al.
        Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
        JAMA. 2010; 304: 967-975
        • Domchek S.M.
        • Friebel T.M.
        • Neuhausen S.L.
        • et al.
        Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
        Lancet Oncol. 2006; 7: 223-229
        • Lu K.H.
        • Kauff N.D.
        Does a BRCA mutation plus tamoxifen equal a hysterectomy?.
        Gynecol Oncol. 2007; 104: 3-4
        • Carlson R.W.
        • Allred D.C.
        • Anderson B.O.
        • et al.
        Breast cancer: clinical practice guidelines in oncology.
        J Natl Compr Canc Netw. 2009; 7: 122-192
        • Venn A.
        • Watson L.
        • Bruinsma F.
        • Giles G.
        • Healy D.
        Risk of cancer after use of fertility drugs with in-vitro fertilization.
        Lancet. 1999; 354: 1586-1590
        • DiSaia P.J.
        • Brewster W.R.
        • Ziogas A.
        • Anton-Culver H.
        Breast cancer survival and hormone replacement therapy.
        Am J Clin Oncol. 2000; 23: 541-545
        • Col N.F.
        • Kim J.A.
        • Chlebowski R.T.
        Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence.
        Breast Cancer Res. 2005; 7: 535-540
        • Million Women Study Collaborators
        Breast cancer and hormone replacement therapy in the million women study.
        Lancet. 2003; 362: 419-427
        • Holmberg L.
        • Anderson H.
        • HABITS steering and data monitoring committees
        HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomized comparison: trial stopped.
        Lancet. 2004; 363: 453-455
        • Holmberg L.
        • Iversen O.-E.
        • Rudenstam C.M.
        • et al.
        Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
        J Natl Cancer Inst. 2008; 100: 475-482
        • Von Schoultz E.
        • Rutqvist L.E.
        • Stockholm Breast Cancer Study Group
        Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.
        J Natl Cancer Inst. 2005; 97: 533-535
        • Loprinzi C.L.
        • Michalak J.C.
        • Quella S.K.
        • et al.
        Megestrol acetate for the prevention of hot flashes.
        N Engl J Med. 1994; 12: 155-158
        • American College of Obstetricians and Gynecologists, Women's Health Care Physicians
        Breast cancer.
        Obstet Gynecol. 2004; 104: 11S-16S
        • Pachman D.R.
        • Jones J.M.
        • Loprinzi C.L.
        Management of menopause-associated vasomotor symptoms: current treatment options, challenges and future directions.
        Int J Womens Health. 2010; 9: 123-135
        • Loprinzi C.L.
        • Pisansky T.M.
        • Fonseca R.
        • et al.
        Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors.
        J Clin Oncol. 1998; 16: 2377-2381
        • Sideras K.
        • Ingle J.N.
        • Ames M.M.
        • et al.
        Coprescription of tamoxifen and medications that inhibit CYP2D6.
        J Clin Oncol. 2010; 28: 2768-2776
        • Thacker H.L.
        Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women.
        J Womens Health. 2011; 20: 1007-1016
        • Goldberg R.M.
        • Loprinzi C.L.
        • O'Fallon J.R.
        • et al.
        Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.
        J Clin Oncol. 1994; 12: 155-158
        • Reddy S.Y.
        • Warner H.
        • Guttuso Jr, T.
        • et al.
        Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial.
        Obstet Gynecol. 2006; 108: 41-48
        • Geller S.E.
        • Shulman L.P.
        • van Breemen R.B.
        • et al.
        Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial.
        Menopause. 2009; 16: 1156-1166
        • Messina M.
        • McCaskill-Stevens W.
        • Lampe J.W.
        Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings.
        J Natl Cancer Inst. 2006; 98: 1275-1284
        • Dorval M.
        • Maunsell E.
        • Taylor-Brown J.
        • Kilpatrick M.
        Marital stability after breast cancer.
        J Natl Cancer Inst. 1999; 91: 54-59
        • Paskett E.
        • Alfano C.M.
        • Davidson M.A.
        • et al.
        Breast cancer survivors' health-related quality of life: racial differences and comparisons to non-cancer controls.
        Cancer. 2008; 11: 3222-3230
        • Kessler R.
        Depression is a timely topic.
        Comp Health Prac Rev. 2003; 8: 6-8
        • Stark D.
        • Kiely M.
        • Smith A.
        • Velikova G.
        • House A.
        • Selby P.
        Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life.
        J Clin Oncol. 2002; 20: 3137-3148
        • Shelby R.A.
        • Golden-Kreutz D.M.
        • Andersen B.L.
        PTSD diagnoses, subsyndromal symptoms, and comorbidities contribute to impairments for breast cancer survivors.
        J Trauma Stress. 2008; 21: 165-172
        • Evans D.L.
        • Staab J.P.
        • Petitto J.M.
        • et al.
        Depression in the medical setting: biopsychological interactions and treatment considerations.
        J Clin Psychiatry. 1999; 60: 40-55
        • Keller M.B.
        • McCullough J.P.
        • Klein D.N.
        • et al.
        A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.
        N Engl J Med. 2000; 342: 1462-1470
        • McDonald M.V.
        • Passik S.D.
        • Dugan W.
        • Rosenfeld B.
        • Theobald D.E.
        • Edgerton S.
        Nurses' recognition of depression in their patients with cancer.
        Oncol Nurs Forum. 1999; 26: 593-599
        • Newell S.
        • Sanson-Fisher R.W.
        • Girgis A.
        • Bonaventura A.
        How well do medical oncologists' perceptions reflect their patients' reported physical and psychosocial problems?.
        Cancer. 1998; 83: 1640-1651
        • Ashbury F.D.
        • Madlensky L.
        • Raich P.
        • et al.
        Antidepressant prescribing in community cancer care.
        Support Care Cancer. 2003; 11: 278-285
        • Sharpe M.
        • Strong V.
        • Allen K.
        • et al.
        Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs.
        Br J Cancer. 2004; 90: 314-320
        • Wang P.S.
        • Simon G.
        • Kessler R.C.
        The economic burden of depression and the cost-effectiveness of treatment.
        Int J Methods Psychiatr Res. 2003; 12: 22-33
        • World Health Organization
        The global burden of disease: 2004 update.
        WHO Press, Geneva, Switzerland2008
        • Dausch B.M.
        • Compas B.E.
        • Beckjord E.
        • et al.
        Rates and correlates of DSM-IV diagnoses in women newly diagnosed with breast cancer.
        J Clin Psychol Med Settings. 2004; 11: 159-169
        • Schwartz L.
        • Drotar D.
        Posttraumatic stress and related impairment in survivors of childhood cancer in early adulthood compared to healthy peers.
        J Pediatr Psychol. 2006; 31: 356-366
        • Sadler I.J.
        • Jacobsen P.B.
        • Booth-Jones M.
        • Belanger H.
        • Weitzner M.A.
        • Fields K.K.
        Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue.
        J Pain Symptom Manage. 2002; 23: 406-416
        • Smith E.M.
        • Gomm S.A.
        • Dickens C.M.
        Assessing the independent contribution to quality of life from anxiety and depression in patients with advanced cancer.
        Palliat Med. 2003; 17: 509-513
        • Mystakidou K.
        • Tsilika E.
        • Parpa E.
        • Katsouda E.
        • Galanos A.
        • Vlahos L.
        Assessment of anxiety and depression in advanced cancer patients and their relationship with quality of life.
        Qual Life Res. 2005; 14: 1825-1833
        • Deshields T.
        • Tibbs T.
        • Fan M.Y.
        • Taylor M.
        Differences in patterns of depression after treatment for breast cancer.
        Psychooncology. 2006; 15: 398-406
        • Peters L.
        • Sellick K.
        Quality of life of cancer patients receiving inpatient and home-based palliative care.
        J Adv Nurs. 2006; 53: 524-533
        • Yen J.Y.
        • Ko C.H.
        • Yen C.F.
        • et al.
        Quality of life, depression, and stress in breast cancer women outpatients receiving active therapy in Taiwan.
        Psychiatry Clin Neurosci. 2006; 60: 147-153
        • Carver C.S.
        • Antoni M.H.
        Finding benefit in breast cancer during the year after diagnosis predicts better adjustment 5 to 8 years after diagnosis.
        Health Psychol. 2004; 23: 595-598
        • Simonelli L.E.
        • Fowler J.
        • Maxwell G.L.
        • Andersen B.L.
        Physical sequelae and depressive symptoms in gynecologic cancer survivors: meaning in life as a mediator.
        Ann Behav Med. 2008; 35: 275-284
        • Carver C.S.
        • Pozo C.
        • Harris S.D.
        • et al.
        How coping mediates the effect of optimism on distress: a study of women with early stage breast cancer.
        J Pers Soc Psychol. 1993; 65: 375-390
        • Shelby R.A.
        • Golden-Kreutz D.M.
        • Andersen B.L.
        PTSD diagnoses, subsyndromal symptoms, and comorbidities contribute to impairments for breast cancer survivors.
        J Trauma Stress. 2008; 21: 165-172
        • Satin J.R.
        • Linden W.
        • Phillips M.J.
        Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis.
        Cancer. 2009; 115: 5349-5361
        • Pinquart M.
        • Duberstein P.R.
        Depression and cancer mortality: a meta-analysis.
        Psychol Med. 2010; 40: 1797-1810
        • Hjerl K.
        • Andersen E.W.
        • Keiding N.
        • Mouridsen H.T.
        • Mortensen P.B.
        • Jørgensen T.
        Depression as a prognostic factor for breast cancer mortality.
        Psychosomatics. 2003; 44: 24-30
        • Giese-Davis J.
        • Collie K.
        • Rancourt K.M.
        • Neri E.
        • Kraemer H.C.
        • Spiegel D.
        Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis.
        J Clin Oncol. 2011; 29: 413-420
        • Williams S.B.
        • O'Connor E.A.
        • Eder M.
        • Whitlock E.P.
        Screening for child and adolescent depression in primary care settings: a systematic evidence review for the US Preventive Services Task Force.
        Pediatrics. 2009; 123: e716-e735
        • Pignone M.P.
        • Gaynes B.N.
        • Rushton J.L.
        • et al.
        Screening for depression in adults: a summary of the evidence for the US Preventive Services Task Force.
        Ann Intern Med. 2002; 136: 765-776
        • Sharp L.K.
        • Lipsky M.S.
        Screening for depression across the lifespan: a review of measures for use in primary care settings.
        Am Fam Physician. 2002; 66: 1001-1008
        • Carlson L.E.
        • Groff S.L.
        • Maciejewski O.
        • Bultz B.D.
        Screening for distress in lung and breast cancer outpatients: a randomized controlled trial.
        J Clin Oncol. 2010; 28: 4884-4891
        • Delgado P.L.
        • Zarkowski P.
        Treatment of mood disorders.
        in: Panksepp J. Textbook of biological psychiatry. Wiley-Lis Inc, Hoboken, NJ2004: 231-266
        • Marangell L.B.
        Augmentation of standard depression therapy.
        Clin Ther. 2000; 22: A25-A38
        • Ng C.G.
        • Boks M.P.
        • Zainal N.Z.
        • de Wit N.J.
        The prevalence and pharmacotherapy of depression in cancer patients.
        J Affect Disord. 2011; 131: 1-7
        • Rodin G Katz M.
        • Lloyd N.
        • Green E.
        • Mackay J.A.
        • Wong R.K.
        Treatment of depression in cancer patients.
        Curr Oncol. 2007; 14: 180-188
        • Costa D.
        • Mogos I.
        • Toma T.
        Efficacy and safety of mianserin in the treatment of depression of women with cancer.
        Acta Psychiatr Scand Suppl. 1985; 320: 85-92
        • van Heeringen K.
        • Zivkov M.
        Pharmacological treatment of depression in cancer patients: a placebo-controlled study of mianserin.
        Br J Psychiatry. 1996; 169: 440-443
        • Morrow G.R.
        • Hickok J.T.
        • Roscoe J.A.
        • et al.
        Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program.
        J Clin Oncol. 2003; 21: 4635-4641
        • Roscoe J.A.
        • Morrow G.R.
        • Hickok J.T.
        • et al.
        Effect of paroxetine hydrocholoride (Paxil) on fatigue and depression in breaset cancer patients receiving chemotherapy.
        Breast Cancer Res Treat. 2005; 89: 243-249
        • Musselman D.L.
        • Somerset W.I.
        • Guo Y.
        • et al.
        A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
        J Clin Psychiatry. 2006; 67: 288-296
        • Carpenter J.S.
        • Storniolo A.M.
        • Johns S.
        • et al.
        Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer.
        Oncologist. 2007; 12: 124-135
        • Hollon S.D.
        • DeRubeis R.J.
        • Shelton R.C.
        • et al.
        Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.
        Arch Gen Psychiatry. 2005; 62: 417-422
        • Brothers B.
        • Yang H.C.
        • Strunk D.
        • Andersen B.L.
        Cancer patients with major depressive disorder: testing a biobehavioral/cognitive behavioral intervention.
        J Consult Clin Psych. 2011; 79: 253-260
        • Frierson G.M.
        • Andersen B.L.
        The psychological aspects of cosmetic and reconstructive surgery.
        in: Sarwer D. Pruzinsky T. Cash T. Persing J. Whitaker L. Breast reconstruction. Lippincott, Williams, & Wilkens, Philadelphia, PA2006: 173-188
        • Yurek D.
        • Farrar W.
        • Andersen B.L.
        Breast cancer surgery: comparing surgical groups and determining individual differences in postoperative sexuality and body change stress.
        J Consult Clin Psychol. 2000; 68: 697-709
        • Andersen B.L.
        In sickness and in health: maintaining intimacy following breast cancer recurrence.
        Cancer J. 2009; 15: 70-73
        • Van't Spijker A.
        • Trijsburg R.W.
        • Duivenvoorden H.J.
        Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980.
        Psychosom Med. 1997; 59: 280-293
        • Andersen B.L.
        • Carpenter K.M.
        • Yang H.C.
        • Shapiro C.L.
        Sexual well-being among partnered women with breast cancer recurrence.
        J Clin Oncol. 2007; 25: 3151-3157
        • Frierson G.M.
        • Thiel D.L.
        • Andersen B.L.
        Body change stress for women with breast cancer: the Breast-Impact of Treatment Scale.
        Ann Behav Med. 2006; 32: 77-81
        • Krychman M.L.
        • Pereira L.
        • Carter J.
        • Amsterdam A.
        Sexual oncology: sexual health issues in women with cancer.
        Oncology. 2006; 71: 18-25
        • Thornton L.M.
        • Carson III, W.E.
        • Shapiro C.L.
        • Farrar W.B.
        • Andersen B.L.
        Delayed emotional recovery after taxane-based chemotherapy.
        Cancer. 2008; 113: 638-647
        • Grady D.
        Management of menopausal symptoms.
        N Engl J Med. 2006; 355: 2338-2347
        • Orr Jr, J.
        • Kelley 3rd, J.
        • et al.
        • SGO Breast Cancer Task Force
        Society of Gynecologic Oncologists position paper: breast cancer care.
        Gynecol Oncol. 2008; 110: 7-12
        • Bachmann G.
        Estradiol-releasing vaginal ring delivery system for urogenital atrophy: experience over the past decade.
        J Reprod Med. 1998; 43: 991-998
        • Kendall A.
        • Dowsett M.
        • Folkerd E.
        • Smith I.
        Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors.
        Ann Oncol. 2006; 17: 584-587
        • Pfeiler G.
        • Glatz C.
        • Konigsberg R.
        • et al.
        Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients.
        Climacteric. 2011; 14: 339-344
        • Beach S.R.
        • Fincham F.D.
        • Katz J.
        Marital therapy in the treatment of depression: toward a third generation of therapy and research.
        Clin Psychol Rev. 1998; 18: 635-661
        • Mead D.E.
        Marital distress, co-occurring depression, and marital therapy: a review.
        J Marital Fam Ther. 2002; 28: 299-314
        • Saxbe D.E.
        • Repetti R.L.
        • Nishina A.
        Marital satisfaction, recovery from work, and diurnal cortisol among men and women.
        Health Psychol. 2008; 27: 15-25
        • Hagedoorn M.
        • Sanderman R.
        • Bolks H.N.
        • Tuinstra J.
        • Coyne J.C.
        Distress in couples coping with cancer: a meta-analysis and critical review of role and gender effects.
        Psychol Bull. 2008; 134: 1-30
        • Yang H.C.
        • Schuler T.A.
        Marital quality and survivorship: slowed recovery for breast cancer patients in distressed relationships.
        Cancer. 2009; 115: 217-228
        • Mclauglin S.A.
        • Wright M.J.
        • Morris K.T.
        • et al.
        Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors.
        J Clin Oncol. 2008; 26: 5213-5219
        • Giuliano A.E.
        • Hunt K.K.
        • Ballman K.V.
        • et al.
        Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
        JAMA. 2011; 305: 569-575
        • Fisher B.
        • Costantino J.P.
        • Wickerham D.L.
        • et al.
        Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
        J Natl Cancer Inst. 1998; 90: 1371-1388
        • Ettinger B.
        • Black D.
        • Mitlak B.
        • et al.
        Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results form a 3 year randomized clinical trial. 1999; 282: 637-645
        • Black D.M.
        • Cummings S.R.
        • Karpf D.B.
        • et al.
        Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.
        Lancet. 1996; 348: 1535-1541
        • Fisher B.
        • Constantino J.P.
        • Redmond C.K.
        • et al.
        Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National surgical adjuvant breast and bowel project (NSABP) B-14.
        J Natl Cancer Inst. 1994; 86: 527-537
        • Hann L.E.
        • Gess C.S.
        • Bach A.m.
        • et al.
        Endometrial thickness in tamoxifen treated patients: correlation with clinical and pathologic findings.
        AMJ Am J Roentgenol. 1997; 168: 657-661